A substrate for cell and/or tissue culture and for micro-patterning cells and/or tissues, wherein the substrate comprises a base layer (1), and a polymer compound layer (2), wherein each of the base layer (1) and the polymer compound layer (2) has an upper surface and a lower surface, each of the upper surface and the lower surface extending in an xy-plane, wherein each of the base layer (1) and the polymer compound layer (2) has a thickness in the z-direction being perpendicular to the xy-plane, wherein the polymer compound layer (2) is stacked on the upper surface of the base layer, wherein the polymer compound layer (2) comprises a first portion (2a), a second portion (2b) and a slit portion (2c), wherein the slit portion (2c) extends along the z-direction from the upper surface of the polymer compound layer (2) through the polymer compound layer (2), thereby at least partly separating the first portion (2a) from the second portion (2b), so that the second portion (2b) is removeable from the upper surface of the base layer (1) independently from the first portion (2a).
The present invention relates to a nucleic acid nanostructure comprising at least one scaffold strand and a plurality of staple strands, wherein said nanostructure, preferably said at least one scaffold strand, comprises at least one nucleic acid sequence encoding a gene. The present invention further relates to a composition comprising a nucleic acid nanostructure, and to a collection of nucleic acid sequences or collection of plasmids encoding a nucleic acid nanostructure. Furthermore, the present invention relates to a nucleic acid nanostructure or composition comprising a nucleic acid nanostructure for use in medicine; preferably for use in a method of preventing, treating and/or diagnosing a disease or disorder. The present invention also relates to a method of expressing a gene from a nucleic acid nanostructure, and to a use of a nanostructure or of a composition for gene expression.
In some example, a method for generating an input tensor representing image data to be encoded by an encoder comprises processing the image data using a selected global transformation to generate a first tensor comprising transformed image data, processing the first tensor by one or more layers of a selected neural network, to generate the input tensor, wherein the input tensor comprises a pre-processed tensor representation of the image data, providing at least one of: a set of configuration parameters for the selected global transformation, a first index representing the selected global transformation, and a second index representing the selected neural network to a decoder, and providing the input tensor for an encoder configured to generate a bitstream representing coded image data.
H04N 19/85 - Procédés ou dispositions pour le codage, le décodage, la compression ou la décompression de signaux vidéo numériques utilisant le pré-traitement ou le post-traitement spécialement adaptés pour la compression vidéo
The present invention relates to the use of TWA1 or a homolog thereof for modifying thermotolerance and/or senescence in plants or plant cells, and further to the use of TWA1 or a homolog thereof as a molecular thermosensitive genetic control switch for gene expression.
The invention provides a computer-implemented method for medical imaging, the method comprising: obtaining X-ray image data from one or more X-ray images acquired by an imaging system comprising an X-ray source, an X-ray detector, and a collimation shutter arranged between the X-ray source and the X-ray detector and configured to collimate X-ray radiation, wherein the X-ray image data is obtained using initial imaging settings, the initial imaging settings comprising initial imaging position settings and initial shutter settings, wherein the initial imaging position settings describe the position of the X-ray source and the X-ray detector in space, wherein the initial shutter settings describe the configuration of the collimation shutter, wherein the X-ray image data comprises collimated image data for a first detector area of the X-ray detector, the first detector area corresponding to an initial field of view (initial FOV) defined by an imaging geometry of the imaging system including the configuration of the collimation shutter, and wherein the X-ray image data comprises non-collimated image data for a second detector area outside of the first detector area, the non-collimated image data resulting from out of focus (OOF) radiation; processing the non-collimated image data to obtain extracted image information; and outputting data based on the extracted image information.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
The present invention relates to a method for in vitro amplification of a linear virus genome, in particular a bacteriophage, expression and self-assembling of the virus, in particular the bacteriophage, in a cell-free expression system as well as a virus 5 or bacteriophage provided by such methods. Further aspects of the invention relate to a synthetic bacteriophage and the use thereof.
The present invention relates to a method of identifying one or more T cells, as well as method of isolating one or more T cells. Further, the invention relates to a method of identifying one or more TCR, a nucleic acid molecule comprising a nucleic acid sequence encoding the TCR identified by the methods of the invention. The invention also relates to a method of generating one or more immune cells. The invention also relates to a host cell comprising a nucleic molecule encoding a TCR identified by the invention or generated by a method of the invention. The invention also relates to a pharmaceutical composition comprising a cell of the invention, or a cell of the invention for use in therapy. Finally, the invention also relates to a method of diagnosing cancer.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The present invention relates to a QTL allele in maize associated with drought resistance and carbon isotope composition as well as specific marker alleles associated with the QTL allele. The present invention further relates methods for identifying maize plants based on screening for the presence of the QTL allele or marker alleles. The invention also relates to methods for modifying drought resistance and carbon isotope composition in maize plants.
A01H 1/00 - Procédés de modification des génotypes
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
9.
PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY
LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (Allemagne)
Inventeur(s)
Kapurniotu, Aphrodite
Tas, Karin
Bernhagen, Jürgen
Abrégé
The present invention relates to a peptide, and to a pharmaceutical composition and a heterocomplex comprising the peptide. Furthermore, the present invention relates to the peptide, the pharmaceutical composition, or the heterocomplex for use in a method of preventing or treating Alzheimer's disease and/or for use in a method of preventing or treating type 2 diabetes. The present invention further relates to the peptide, the pharmaceutical composition, or the heterocomplex for use in a method of diagnosing Alzheimer's disease and/or for use in a method of diagnosing type 2 diabetes. The present invention also relates to a kit for the in vitro or in vivo detection of amyloid fibrils or aggregates, or for the diagnosis of Alzheimer's disease and/or type 2 diabetes in a patient. Moreover, the present invention relates to the use of the peptide or of the heterocomplex in an in vitro assay for the detection of monomeric islet amyloid polypeptide (LAPP), monomeric Aβ40 (42), amyloid fibrils, or amyloid aggregates.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
10.
MODIFIED IMMUNE CELLS FOR TREATING AND/OR PREVENTING METASTASIS
The present invention relates to modified immune cells, in particular modified NK cells and T cells and tumor-infiltrating lymphocytes (TILs). The present invention relates to the modified NK cells and T cells and TILs for use in the treatment and/or prevention of cancer, in particular in the treatment and/or prevention of metastases. The present invention further relates to a method of generating modified NK cells or T cells or TILs. The present invention further relates to compositions comprising said modified immune cells.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
Technische Universität München - Klinikum Rechts der Isar (Allemagne)
Inventeur(s)
Wurzer, Alexander Josef
Wester, Hans-Jürgen
Eiber, Matthias Johannes
Abrégé
The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.
This disclosure relates to a method for the additive manufacturing of an object, including supplying a strand-shaped starting material to a friction arrangement, and accelerating the starting material along an output direction through the friction arrangement, to apply the starting material onto a construction platform and/or onto already manufactured areas of the object for manufacturing the object, wherein the starting material is at least partially liquefied and/or at least partially plasticized and/or at least partially broken down into particles by the friction arrangement. This disclosure also relates to a manufacturing device to perform such methods.
B22F 10/25 - Dépôt direct de particules métalliques, p. ex. dépôt direct de métal [DMD] ou mise en forme par laser [LENS]
B22F 12/13 - Moyens de chauffage auxiliaires pour préchauffer le matériau
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
A manufacturing device for manufacturing an object in layers includes at least one transfer platform with a transfer platform surface, at least one application unit configured to apply at least one treatment layer and at least one material layer which together form a pre-material layer of the object, to the transfer platform surface, wherein the pre-material layer extends at least in a first direction (x) and/or in a second direction (y), and a construction platform configured to receive at least the at least one material layer of the pre-material layer from the transfer platform so that the object is manufactured in layers on the construction platform in a third direction (z).
B29C 64/147 - Procédés de fabrication additive n’utilisant que des matériaux solides utilisant des matériaux stratifiés, p. ex. fabrication d’objets stratifiés ou matériau stratifié prédécoupé selon les sections en coupe de l’objet en 3D
B22F 10/14 - Formation d’un corps vert par projection de liant sur un lit de poudre
The present invention relates to in vitro methods for determining the vitamin status of a subject, in particular health related vitamins, such as B2, B6, B12 and/or D3. The present invention further relates to a kit and an immunographic device for in vitro determining the vitamin status of a subject.
G01N 33/82 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des vitamines
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
15.
A METHOD FOR GENETIC MODIFICATION FOR HIGH GC CONTENT MICROORGANISMS
The present invention relates to a method of genetically modifying a GC rich microorganism. The present invention further relates to a genetically modified GC rich microorganism. Furthermore, the present invention relates to a composition comprising a RNA-guided endonuclease, at least one guide RNA (gRNA), and optionally donor DNA. The present invention also relates to a method of preparing a target compound, e.g. an acetyl-CoA-based hydrophobic compound, and/or an oil having a specific fatty acid profile, e.g. high oleic oil, using a genetically modified GC rich microorganism.
Provided is a method for the preparation of a composition comprising dissolved [18F]fluoride ions which is suitable for radiofluorination, said method comprising the steps of: providing an aqueous solution comprising water and [18F]fluoride ions; passing the aqueous solution through a solid phase extraction device comprising an anion exchange resin in order to trap [18F]fluoride ions on the anion exchange resin and to separate the [18F]fluoride ions trapped on the anion exchange resin from water; eluting [18F]fluoride ions from the anion exchange resin by passing an elution composition comprising an organic solvent and a salt of an alkanoic acid through the solid phase extraction device; obtaining a composition as an eluate which comprises the organic solvent, the salt of the alkanoic acid, and dissolved [18F]fluoride ions. Moreover, provided are the composition comprising dissolved [18F]fluoride ions, and a method for the preparation of a radiofluorinated organic compound, which involves the preparation of the composition comprising dissolved [18F]fluoride ions.
There is provided herein compound of formula (I) as defined in Formula (I), wherein Ra, Rb, Rc, A and p have meanings given in the description, and pharmaceutically-acceptable salts and solvates thereof, which compounds are useful in the treatment of diseases in which pan-immunoproteasome inhibition is desired or required, and particularly in the treatment of cancer.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Bayerische Motoren Werke Aktiengesellschaft (Allemagne)
TECHNISCHE UNIVERSITÄT MÜNCHEN (Allemagne)
Inventeur(s)
Froede, Christian
Renner, Anton
Forstner, Peter
Froeschl, Joachim
Tippe, Laurenz
Abrégé
Embodiments of the present invention provide a method of activating a vehicle function of a vehicle. The vehicle comprises a plurality of energy paths and a plurality of energy consumers, with each energy path of the plurality of energy paths comprising at least one energy consumer of the plurality of energy consumers. The method comprises receiving a command to activate the vehicle function. The command to activate the vehicle function specifies an identifier of the vehicle function. The method further comprises, in response to the command to activate the vehicle function, determining an identifier of an energy path of the plurality of energy paths associated with the identifier of the vehicle function and selectively activating the energy path to provide electrical energy to at least one energy consumer of the plurality of energy consumers. The energy consumer is configured to perform the vehicle function.
B60R 16/023 - Circuits électriques ou circuits de fluides spécialement adaptés aux véhicules et non prévus ailleursAgencement des éléments des circuits électriques ou des circuits de fluides spécialement adapté aux véhicules et non prévu ailleurs électriques pour la transmission de signaux entre des parties ou des sous-systèmes du véhicule
B60R 16/03 - Circuits électriques ou circuits de fluides spécialement adaptés aux véhicules et non prévus ailleursAgencement des éléments des circuits électriques ou des circuits de fluides spécialement adapté aux véhicules et non prévu ailleurs électriques pour l'alimentation des sous-systèmes du véhicule en énergie électrique
19.
MULTI-DIMENSIONAL TOOL ADJUSTMENT BASED ON ACOUSTIC SIGNAL
A method for generating an acoustic calibration signal for adjusting a tool in a plurality of dimensions relying on acoustic feedback. Each dimension of the plurality of dimensions corresponds to a respective degree of freedom of the tool. The method comprises generating the calibration acoustic signal having an acoustic property for each dimension of the plurality of dimensions, wherein each of the acoustic properties varies towards a corresponding predetermined value when the tool is being adjusted in the corresponding dimension towards a corresponding predetermined target adjustment. A related method and a related alignment system for adjusting a tool in a plurality of dimensions.
G01S 7/52 - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
20.
LITHOGRAPHIC MASKING DEVICE AND PARALLEL-FLOW PROVIDER DEVICE FOR A STOP FLOW LITHOGRAPHY APPARATUS
A lithographic masking device for a stop flow lithography apparatus comprises a substrate, a lithographic mask arranged above the substrate, and a first flow channel defining an inner volume thereof. The substrate is adapted to transmit blue or UV light, wherein the blue or UV light comprises a wavelength in a wavelength range from 320 nm to 500 nm. Side portions and an upper portion of the first flow channel are arranged above the substrate, such that the inner volume of the flow channel is arranged above the lithographic mask and that a shortest distance between the lithographic mask and the inner volume of the first flow channel is at most 30 µm.
The invention is notably directed to a composition including a plurality of double-stranded oligodeoxynucleotides (dsODNs). The dsODNs of said plurality have a same length of between 47 and 300 bp (e.g., between 80 and 150 bp, or between 85 and 130 bp). The dsODNs are structured according to a same template structure, which consists of an orderly set of sequence portions having respective lengths that are constant across all the dsODNs of said plurality. The orderly set of sequence portions includes a first random segment, a first sequencing adapter, a second random segment, a second sequencing adapter, and a third random segment. Such segments are consecutively arranged to form a sequence. Each of the random segments of the dsODNs of said plurality consists of essentially random permutations of nucleotides, whereas the first and second sequencing adapters of the dsODNs of said plurality consist, independently of each other, of essentially a same sequence of nucleotides. The above template structure gives rise to partly random DNA, which can be operated for verification and/or authentication purposes. The above sequence structure allows the composition to be used as a mathematical one-way function and as a physical unclonable function (PUF). I.e., it can be used as a physical fingerprint, which can be challenged to verify or authenticate a product, an object, or any entity, with which the composition is associated. The same composition can be subjected to multiple challenges, hence providing higher certainty as to an associated entity. The underlying technology is scalable. Samples of the composition can be distributed to multiple users, unlike usual PUF objects. Accordingly, the proposed composition can adequately be used for securing objects or entities. The invention is further directed to methods of producing such a composition, the use of such a composition, a set comprising such a composition associated with an entity, and methods of verifying entities associated with such compositions.
Disclosed is a method of transmitting data via a communication channel (12), comprising the following steps: encoding the data using a Hadamard code into a plurality of Hadamard- codewords of length M, generating a set of M coherent light beams (20) having mutually different wavelengths, phase-modulating the set of M coherent light beams (20) according to Hadamard-codewords, multiplexing said set of M phase-modulated coherent light beams (20) into a transmission end of said communication channel, at a receiving end, demultiplexing said M phase-modulated coherent light beams (20), applying wavelength shifts to said received phase-modulated light beams (20), such that all of said M phase modulated light beams (20) acquire a same detection wavelength, and coupling said M wavelength-shifted phase- modulated light beams (20) into M entry ports (38) of a joint detection receiver (JDR) (36).
The present invention relates the use of an anti-inflammatory agent for inhibiting and/or preventing a cardiovascular complication in a subject suffering from a respiratory disease. The present invention also relates to the use of an anti-inflammatory agent for preserving cardiac innervation in a subject suffering from respiratory disease.
The present invention relates to a method for producing microbial lipids, optionally for producing microbial lipids and protein biomass and/or aromatic compounds. The present invention further relates to a use of a microbial lipid. The present invention also relates to a composition comprising at least five enzymes.
A23D 7/02 - Compositions à base d'huiles ou de graisses comestibles contenant une phase aqueuse, p. ex. margarines caractérisées par leur production ou leur traitement
A23G 1/36 - Produits à base de cacao, p. ex. chocolatLeurs succédanés caractérisés par la composition caractérisés par les matières grasses utilisées
A23J 1/00 - Préparation des compositions à base de protéines pour l'alimentationOuverture des œufs par grandes quantités et séparation du jaune du blanc
A23L 27/24 - Épices, agents aromatiques ou condiments synthétiques préparés par fermentation
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
C12P 21/00 - Préparation de peptides ou de protéines
25.
POLYSACCHARIDE OR POLYSACCHARIDE MIXTURE PRODUCED BY PAENIBACILLUS POLYMYXA
The invention relates to a polysaccharide or a polysaccharide mixture produced by a genetically modified production organism Paenibacillus polymyxa, as well as to a method for the preparation of the polysaccharide or polysaccharide mixture.
TECHNISCHE UNIVERSITÄT DRESDEN, KÖRPERSCHAFT DES ÖFFENTLICHEN RECHTS (Allemagne)
TECHNISCHE UNIVERSITÄT MÜNCHEN (Allemagne)
ECOLOGIC-COMPUTING GMBH (Allemagne)
Inventeur(s)
Cabrera Guerrero, Juan Alberto
Hofmann, Pit
Fitzek, Frank Hanns Paul
Boche, Holger
Abrégé
A computing system (100) and a corresponding method (200) are disclosed, wherein the computing system (100) comprises a processor (102) which is designed: to receive a computing request (106), which comprises a computing task (108) and associated conditions (110), the conditions (110) comprising an energy consumption condition and a latency condition and/or an accuracy condition; to select at least one computing unit from a plurality of computing units (104(n = 1 to N)), each computing unit of the plurality of computing units having a computing architecture, at least one computing unit of the plurality of computing units having a computing architecture different from at least one other computing unit of the plurality of computing units (104(n = 1 to N)), and each computing unit (104(n)) being assigned computing architecture information (112(n)) containing information about properties of the n computing unit with respect to the energy consumption and at least one latency and/or accuracy in an execution of a computing task (108); wherein the at least one computing unit is selected using the computing architecture information (112(n = 1 to N)).
Disclosed herein is a process for the manufacture of a cathode active material with a coreshell structure. The process includes the steps of:
(a) providing a particulate electrode active material according to a general formula Li1+xTM1−xO2, where TM is a combination of metals and includes Ni and Mn, and, optionally, at least one element selected from Al, Mg, Ba and transition metals other than Ni and Mn, and x is in the range of from 0.075 to 0.2, where at least 50 mole-% of the metal of TM is Mn,
(b) treating the particulate electrode active material with an aqueous buffer solution with a pH value in the range of from 2.0 to 10.5,
(c) removing the liquid phase by a solid-liquid separation method, and
(d) treating the residue from step (c) at a temperature in the range of from 180 to 750° C.
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
The present invention relates to a sensor for non-invasive optoacoustic measurements of biomechanical and/or morphological features of skin and/or other tissue.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
29.
DETECTION OF MOLECULAR BIOLOGICAL OBJECTS, CELLULAR BIOLOGICAL OBJECTS AND CELL AGGREGATES USING QUANTITATIVE PHASE-CONTRAST MICROSCOPY
Disclosed herein is a method for detecting cell aggregates of biological cells using a quantitative phase-contrast microscope, a device for detecting cell aggregates of biological cells, a method for detecting cellular and/or molecular biological objects using a quantitative phase-contrast microscope and a device for detecting cellular and/or molecular biological objects. The method for detecting cell aggregates of biological cells using a quantitative phase-contrast microscope comprises preparing a suspension, the suspension comprising a viscoelastic fluid and biological cells from a sample, wherein the viscoelastic fluid comprises a shear-thinning polymer having a molecular weight between 2 MDa and 10 MDa and wherein a mass fraction of the shear-thinning polymer in the suspension is less than 0.2%. A flow of the suspension is generated along a microfluidic channel to viscoelastically focus cell aggregates in the suspension in a focal plane of the quantitative phase-contrast microscope. One or more phase shift images of the biological cells in the suspension are taken using the quantitative phase-contrast microscope and cell aggregates are identified in the one or more phase shift images.
G01N 15/01 - Recherche de caractéristiques de particulesRecherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux spécialement adaptée aux cellules biologiques, p. ex. aux cellules sanguines
G01N 15/10 - Recherche de particules individuelles
G01N 15/1404 - Manipulation du flux, p. ex. focalisation hydrodynamique
G01N 15/1409 - Manipulation des échantillons, p. ex. injection des échantillons
30.
PROCESS AND PLANT FOR PRODUCING A REACTION PRODUCT
What is proposed is a process (100, 200) for producing a process product, wherein hydrogen is provided using a water electrolysis (104, 150), wherein the hydrogen or a portion thereof is subjected to an exothermic reaction with carbon dioxide to liberate heat and obtain a product mixture containing the process product, wherein the product mixture or a portion thereof is subjected to a distillation using one or more distillation columns (122) and wherein the one or at least one of the two or more distillation columns (122) is heated using heat. It is envisaged here that at least a portion of the heat is provided using a heating system (210) comprising one or more heat pumps (201) and one or more heat storage units (202), which is supplied with the heat generated in the process. The present invention also provides a corresponding plant.
Helmholtz Zentrum München - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH) (Allemagne)
Technische Universität München (Allemagne)
Inventeur(s)
Ganz, Hilary
Engelbrecht, Lisa
Scheel, Christina
Bausch, Andreas
Buchmann, Benedikt
Abrégé
The present invention relates to an in vitro method of generating cells capable of differentiating to a multicellular organoid unit that morphologically and/or functionally recapitulates invasive and/or ductal cell growth. The present invention further relates to a method of screening for an anti-migratory drug using a multicellular organoid unit obtained in the in vitro method. Additionally, the present invention relates to a culture medium and the respective use of said culture medium in any of said methods according to the present invention.
The present disclosure relates to optical fibers (100) for signal transmissions. The disclosure proposes an optical fiber (100), an optical link (200), and a corresponding method for assembling the optical fiber (100). The optical fiber (100) comprises two or more consecutively arranged segments (102a, 102b) and is configured to transmit an optical signal associated with a central wavelength. Each segment of the two or more segments (102a, 102b) is associated with a respective dispersion parameter at the central wavelength, wherein the respective dispersion parameter of at least one segment of the two or more segments (102a, 102b) is positive, and wherein the respective dispersion parameter of at least one other segment of the two or more segments (102a, 102b) is negative.
The invention relates to a method (200) for producing a process product in which a reactant mixture (1) is fed to a reactor (10) and reacted in the reactor (10) in an exothermic reaction having an activation energy, the method comprising a start-up operation (210) in which at least part of the activation energy is provided using one or more start-up heaters (17), wherein the method comprises a production operation (220) carried out after the start-up operation (210), in which at least part of the activation energy is provided using thermal energy generated in the exothermic reaction, and wherein a load is reduced (222) during the production operation (220), in which an amount of the process product produced per unit time in the reactor (10) is reduced. According to the invention, the start-up heater (17) or at least one of the plurality of start-up heaters (17) is operated during the load reduction (222). The invention also relates to a corresponding system (100).
B01J 8/00 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solidesAppareillage pour de tels procédés
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
B01J 8/04 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solidesAppareillage pour de tels procédés avec des particules immobiles, p. ex. dans des lits fixes le fluide passant successivement à travers plusieurs lits
The present invention provides nuclease-resistant nucleic acid nanostructures, pharmaceutical compositions thereof, pharmaceutical and diagnostic uses thereof as well as a method of producing nucleic acid nanostructures.
The present invention provides a novel in vitro method of selecting DNAzymes with self-cleaving activity, novel DNAzymes and their use for the production of single stranded DNA.
The field of the invention relates to a transgenic animal model for studying human diseases. In particular, disclosed herein is a transgenic ungulate for studying human cardiomyopathies. For example, a transgenic ungulate is disclosed harbouring a knock-in of a transgene comprising at least a portion of a human PLN gene containing a mutation that results in an expression of at least a portion of a human PLN mutant protein correlated with a cardiomyopathy phenotype in human subjects. Advantageously, the transgenic ungulate as disclosed herein is a transgenic pig and/or the human PLN mutant protein is a human PLN R14del mutant protein.
A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
A01K 67/0278 - Vertébrés knock-in, p. ex. vertébrés humanisés
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/877 - Techniques de production de nouveaux embryons clonés de mammifères
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
37.
DETECTION OF CELL AGGREGATES USING QUANTITATIVE PHASE-CONTRAST MICROSCOPY
Disclosed herein is a method for detecting cell aggregates of biological cells using a quantitative phase-contrast microscope and a device for detecting cell aggregates of biological cells using said method. The method comprises preparing a suspension comprising biological cells from a sample. A flow of the suspension is generated along a microfluidic channel to viscoelastically and/or hydrodynamically focus cell aggregates in the suspension in a focal plane of the quantitative phase-contrast microscope. One or more phase shift images of the biological cells in the suspension are taken using the quantitative phase-contrast microscope. Cell aggregates in the one or more phase shift images are identified. The sample is a whole blood sample or a blood fraction sample and identifying cell aggregates in the one or more phase shift images comprises identifying platelet aggregates in the one or more phase shift images.
G01N 15/1404 - Manipulation du flux, p. ex. focalisation hydrodynamique
G01N 15/01 - Recherche de caractéristiques de particulesRecherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux spécialement adaptée aux cellules biologiques, p. ex. aux cellules sanguines
G01N 15/1433 - Traitement du signal utilisant la reconnaissance d’image
38.
A METHOD AND SYSTEM FOR IDENTIFICATION OF MALICIOUS CLIENTS WITH SECURE AGGREGATION OF DATA FROM A PLURALITY OF CLIENTS
A computer-implemented method for secure aggregation of data from a plurality of clients. The method comprises requesting data from the plurality of clients, and receiving a plurality of masked data portions from the plurality of clients, wherein the plurality of clients are grouped into a plurality of partially overlapping client groups, and each masked data portion is associated with one of the client groups. The method further comprises aggregating the masked data portions of each client group to obtain a plurality of group data aggregates, wherein each group data aggregate is associated with a respective client group, and estimating, based on a quality metric for each of the plurality of group data aggregates, a subset of malicious clients of the plurality of clients. The method further comprises determining a benign data aggregate based on a remaining plurality of benign clients, wherein the benign clients do not form part of the malicious clients.
The present invention relates to systems and methods for performing a puncturing operation with improved puncture precision. The invention refers to a monitoring system comprising a first magnetic sensor attachable to a puncturing instrument (20), a second magnetic sensor (14) supportable by an endoscopic instrument (30), a field generator (16) configured for generating a variable magnetic field, and a processing unit. The processing unit (18) determines a relative position of the first magnetic sensor with respect to the second magnetic sensor and generates positional data encoding such relative position. The invention further refers to a puncturing system (100) comprising such a monitoring system (10), to a related method of generating positional data, and to a related storage device.
Provided herein is a method for treating a lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of at least one PD-1 pathway agonist.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
Deutsches Zentrum für Luft- und Raumfahrt e.V. (Allemagne)
Technische Universität München (Allemagne)
Inventeur(s)
Albu-Schäffer, Alin
Sachtler, Arne
Abrégé
The invention relates to a dynamic nonlinear system having a plurality of degrees of freedom. The system has at least one potential element, and eigenmodes of the system are produced by means of the potential element. A potential is produced by means of the at least one potential element, and the potential causes an acceleration tangential to the basic trajectories of the system, a basic trajectory being a trajectory of the potential-free system.
Provided are novel SST receptor ligand compounds suitable for the imaging and/or the treatment of neuroendocrine tumors. These SST receptor ligand compounds are comprised of a SST binding motif, a silicon-fluoride acceptor group which can be labeled with 18F by isotopic exchange of 19F by 18F or which is labeled with 18F, a chelating group suitable for forming a chelate with a radioactive or non-radioactive cation, and a hydrophilic amino acid unit or a sequence of such units.
The disclosure provides methods and compositions for treating HBV. Disclosed is an HBcAg particle, comprising HBV core proteins from at least two different HBV genotypes, and a vaccine vector comprising a nucleotide sequence having ≥90% sequence identity to SEQ ID NO: 5. Disclosed are respective pharmaceutical compositions and their uses in therapy, for medicament manufacture and a vaccination method. Said vaccination method comprises administering to a human (i) a first dose and (ii) a second dose of an HBcAg particle and of an HBsAg, and (iii) a dose of a vaccine vector that expresses a HBsAg from HBV genotype A, a HBcAg from HBV genotype D, a HBsAg having ≥90% sequence identity to SEQ ID NO: 7, a HBcAg having ≥90% sequence identity to SEQ ID NO: 8 or 17, and an RT domain having ≥90% sequence identity to SEQ ID NO: 9.
The invention relates to a method (100-300) for creating a synthesis product, which comprises an electrochemical preparation of one or more synthesis reactants using a high-temperature electrolysis unit (1) and an at least partially exothermic conversion of at least the one or more synthesis reactants using a reaction system (2) to obtain waste heat, wherein at least a part of the waste heat is used to provide steam that is supplied to the high-temperature electrolysis unit (1), and wherein the method (100-300) comprises a first method mode and a second method mode. In the reaction system (2), less of the one or more synthesis reactants is converted per unit time in the first method mode than in the second method mode, and the high-temperature electrolysis unit (1) or at least a portion of the high-temperature electrolysis cells contained in the high-temperature electrolysis unit (1) are operated in the second method mode with a lower steam use than in the first method mode. The present invention also relates to a corresponding system.
The present invention relates to a nucleic acid nanostructure comprising a first surface and a second surface, wherein said first surface and said second surface are located at opposing sides of said nanostructure, wherein said first surface comprises at least a first targeting agent and said second surface comprises at least a second targeting agent and at least a third targeting agent. The present invention further relates to a composition comprising a nucleic acid nanostructure. The invention also relates to a nanostructure and a composition for use in medicine, and to a nanostructure and a composition for use in a method of preventing or treating a disease. Furthermore, the present invention relates to a method of preparing a nanostructure and to a use of a nanostructure for binding first target and the second target.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
46.
CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY
The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.
The present invention relates to the field of identifying maize plants with an improved early plant vigor and early plant height. Further, there is provided a specific set of markers diagnostic for a chromosomal region of about or less than 0.68 Mb on chromosome 2 of Zea mays, said region defining a quantitative trait locus (QTL) locus that affects sensitivity to cold stress, early vigor and early plant height at stages V4 and V6 and maximum potential quantum efficiency of photosystem II. Methods and means for detecting the desired phenotype are also provided. Finally, uses of the QTL-bearing chromosomal region for the manufacture and/or identification of a plant of the genus Zea having early plant vigor are provided.
The disclosure relates to a method for identification via channels in a system having a plurality of data processing devices. The method comprises selecting, in a first data processing device, an identifier indicative of a target second data processing device of a plurality of second data processing devices; determining, in the first data processing device, an outer codeword from the identifier using an outer code comprising a first outer code and a second outer code; determining, in the first data processing device, an optical orthogonal codeword from the outer codeword using an optical orthogonal code; determining, in the first data processing device; a randomly selected codeword from the optical orthogonal codeword using an error correction code; and emitting the selected codeword from the first data processing device via a channel. Further, a computer program product and a system for identification via channels are provided.
H04L 27/26 - Systèmes utilisant des codes à fréquences multiples
H03M 13/15 - Codes cycliques, c.-à-d. décalages cycliques de mots de code produisant d'autres mots de code, p. ex. codes définis par un générateur polynomial, codes de Bose-Chaudhuri-Hocquenghen [BCH]
H04L 1/00 - Dispositions pour détecter ou empêcher les erreurs dans l'information reçue
49.
DEVICE AND METHOD FOR PERFORMING COMMUNICATION CHANNEL EQUALIZATION IN A PLURALITY OF CHANNEL SCENARIOS USING A NEURAL NETWORK-BASED EQUALIZER
A device and a method for performing communication channel equalization in a plurality of channel scenarios using a neural network-based equalizer (NNE) are provided. The device receives one or more characteristics of a communication channel for each of the plurality of channel scenarios. Then, the device controls the NNE to equalize the one or more characteristics of the communication channel for a respective channel scenario of the plurality of channel scenarios based on one of a plurality of first parameter sets and based on a second parameter set. Each of the plurality of first parameter sets corresponds to one of the channel scenarios and the second parameter set is common for the plurality of channel scenarios.
The invention concerns a sensor device (1) for detecting the presence of one or more molecules (20) and/or of a class of molecules (20); comprising at least one first (nano-)structure (2); at least one second structure (3); at least one joining portion (4) respectively connecting the at least one first (nano-)structure (2) and the at least one second structure (3) and configured to allow a relative mobility between the at least one first (nano-)structure (2) and the at least one second structure (3), wherein the at least one joining portion (4) is an element separate from and connected to the at least one first (nano-)structure (2) and the at least one second structure (3) or wherein the at least one joining portion (4) is formed integrally with the at least one first (nano-)structure (2) and/or with the at least one second structure (3); one binding structure (5), especially one binding structure (5) per joining portion (4), configured to bind with a molecule, the presence of which is to be detected, wherein the binding structure (5) is located on the at least one first (nano-)structure (2) or on the at least one second structure (3) or on the at least one joining portion (4) such that said allowed relative mobility between the at least one first (nano-)structure (2) and the at least one second structure (3) is changed, especially limited, in a bound state of the binding structure (5) as compared to an unbound state of the binding structure (5); and a detecting means (100) for detecting said relative mobility between the at least one first (nano-)structure (2) and the at least one second structure (3).
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
51.
PORTABLE TESTING DEVICE FOR TESTING SUSCEPTIBILITY OF A BIOLOGICAL PROBE TO ONE OR MORE BIOACTIVE SUBSTANCES
The invention refers to a testing device (to) for testing the susceptibility of a biological probe to one or more bioactive substances. The testing device comprises a liquid-impermeable first substrate (12), a second substrate (14) arranged or arrangeable over the first substrate (12), wherein the second substrate (14) is liquid-permeable and liquid-impregnable, and a third substrate (16) arranged or arrangeable over the second substrate (14), wherein the third substrate (16) is liquid-impermeable. The first substrate and/or the third substrate are configured for encapsulating the second substrate. At least a portion of the second substrate (14) is exposable to an environment of the testing device for receiving the biological probe. The invention further refers to a testing kit comprising such a testing device and at least one of one or more bioactive substances, a biological culture medium, and a bacterial marking substance configured for undergoing a property change in the presence of bacteria. The invention further refers to a corresponding method of testing the susceptibility of a biological probe to one or more bioactive substances.
The present invention relates to compounds having a structure according to general formula I or II or III for use in the treatment of non-viral infections or a disease caused by a non-viral infection. The present invention relates to compounds having a structure according to general formula III and to pharmaceutical compositions comprising at least one of said compounds. The present invention further relates to a method of treating non-viral infections or a disease caused by a non-viral infection.
C07D 233/94 - Radicaux nitro liés en position 4 ou 5 avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre, liés aux autres chaînons du cycle
Disclosed herein is a method for parallelized probing of a plurality of samples, a sensor chip for parallelized probing of a plurality of samples, a sensing device for parallelized probing of a plurality of samples, and a measurement system for parallelized probing of a plurality of samples. The method comprises providing a sensor chip, the sensor chip comprising a sensing layer arranged in or on a substrate and a measurement volume adjacent to the sensing layer. The sensing layer comprises a plurality of sensing elements, each of which is configured to generate a sensor signal characterizing a physical observable in the vicinity of the respective sensing element. A carrier fluid comprising a plurality of sample objects is provided to the measurement volume, wherein each of the sample objects comprises or forms a respective sample. A number of sample objects in the measurement volume is controlled such that the sample objects form a self-organized structure in the measurement volume. The self-organized structure is a structure in which the arrangement of the sample objects is at least in part defined by interactions between the sample objects themselves. A measurement is performed on one or more of the samples while the sample objects are arranged in the self-organized structure, wherein a measurement on a sample is performed using one or more sensing elements arranged adjacent to the respective sample object in the self-organized structure.
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
54.
FUEL CELL SYSTEM AND METHOD FOR OPERATING THE SAME
A fuel cell system arranged for the conversion of pure hydrogen comprising a) at least one fuel cell comprising an anode, a cathode and an electrolyte, and arranged for an internal reformation of methane, b) a fuel conduit connecting a fuel conduit inlet with an anode inlet, c) an anode exhaust conduit connecting an anode outlet and a methanation unit capable of producing methane from anode exhaust, and d) a methanation unit exhaust conduit connecting a methanation unit exit and the fuel conduit, and e) a water removal and/or water condenser unit coupled to the methanation unit exhaust conduit, wherein the fuel introduced into an inlet of the fuel conduit is pure hydrogen, and the amount of methane produced in the methanation unit is equal to the amount of methane reformed inside of the fuel cell so that the content of methane cycling through the fuel cell system is constant.
H01M 8/0637 - Reformage interne direct à l’anode de l’élément à combustible
C07C 1/10 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir d'oxydes de carbone à partir de monoxyde de carbone avec de la vapeur d'eau
C25B 1/042 - Hydrogène ou oxygène par électrolyse de l'eau par électrolyse de la vapeur
H01M 8/04014 - Échange de chaleur par des fluides gazeuxÉchange de chaleur par combustion des réactifs
H01M 8/04119 - Dispositions pour la commande des paramètres des réactifs, p. ex. de la pression ou de la concentration des réactifs gazeux avec apport simultané ou évacuation simultanée d’électrolyteHumidification ou déshumidification
H01M 8/0612 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux à partir de matériaux contenant du carbone
H01M 8/18 - Éléments à combustible à régénération, p. ex. batteries à flux REDOX ou éléments à combustible secondaires
The present invention relates to a nucleic acid nanostructure comprising one or more, preferably at least two, targeting agent(s) and a plurality of dye molecules, preferably at least to dye molecules. The present invention further relates to a composition, preferably pharmaceutical composition, comprising a nucleic acid nanostructure. The present invention also relates to a nanostructure or composition for use in medicine, preferably for use in medical imaging, and for use in a method of preventing, treating, and/or diagnosing a disease. Furthermore, the present invention relates to a method of labelling a target in a sample, to the use of a nanostructure as a stain, and to a kit. Moreover, the present invention further relates to a method of preparing a nanostructure. The present invention further relates to a method of identifying a targeting agent combination having a desired property, a desired effect, and/or a desired spatial organization, and to a method of producing a bi- or multispecific targeting agent-comprising molecule. Furthermore, the present invention relates to a method of screening a sample for a target having at least two target molecules.
Provided is a PSMA-targeted ligand compound, which is a compound of formula (1) or a salt thereof, wherein RTis a PSMA binding group; L is a linking group; Rcis a trivalent coupling group; Rsis a silicon-containing moiety of the formula -C(O)-Rs3-SiRS1RS2OH, wherein RS1and RS2are independently selected from C3-C10 alkyl, and are preferably tert-butyl, and RS3is a group comprising a 6 membered aromatic ring, and is preferably benzenediyl; RAis an amino acid unit; and RCHis selected from (i) a branched-chain, acyclic chelating moiety having 4 amino groups, and (ii) a chelate moiety, wherein a radioisotope selected from 99mTc, 94mTc, 186Re and 188Re is chelated by the branched-chain, acyclic chelating moiety having 4 amino groups. The PSMA-targeted ligand compound in accordance with the invention is suitable for radiopharmaceutical applications, such as radioguided surgery.
The present invention relates to a method of reducing a salt content of a hydrolysate which comprises salt. The present invention further relates to a method of producing a target product, preferably a microbial oil, comprising providing a hydrolysate with reduced salt content and cultivating a microorganism, preferably an oleaginous microorganism, using a growth medium comprising the hydrolysate with reduced salt content.
C12P 19/14 - Préparation de composés contenant des radicaux saccharide préparés par action d'une carbohydrase, p. ex. par action de l'alpha-amylase
C12P 19/16 - Préparation de composés contenant des radicaux saccharide préparés par action d'une alpha-1, 6 glucosidase, p. ex. amylose, amylopectine déramifiée
C12P 19/20 - Préparation de composés contenant des radicaux saccharide préparés par action d'une exo-1, 4 alpha-glucosidase, p. ex. dextrose
C12P 19/22 - Préparation de composés contenant des radicaux saccharide préparés par action d'une bêta-amylase, p. ex. maltose
C13K 1/02 - GlucoseSirops glucosés obtenus par saccharification de matières cellulosiques
C13K 13/00 - Sucres non prévus ailleurs dans la présente classe
58.
CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Azhdarinia, Ali
Ghosh, Sukhen C.
Kossatz, Susanne
Ludwig, Beatrice Stefanie
Weber, Wolfgang
Koller, Lena
Abrégé
The present invention relates to conjugate compounds comprising a disease-targeting moiety and at least one PARP inhibitor moiety and pharmaceutical compositions comprising the conjugate compounds. The present invention relates to the use of the conjugate compounds for use in the treatment of cancer. The present invention further relates to methods of treatment of cancer and for patient selection.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
The present invention relates to conditionally switchable nanostructures, and systems comprising the same. In particular, the present invention pertains to a method for linking the identification of at least one molecule to a conformational reconfiguration of a nanostructure. The invention is further based on the finding that coupling molecules, such as antibodies or antigen binding fragments, can stabilize subunit interactions of nanostructures at otherwise unfavourable conditions. Additionally, the present invention also relates to a system comprising the nanostructures of this invention as well as methods for utilizing the nanostructures or the system of this invention. Finally, substances and/or compositions comprising at least one or a plurality of nanostructures for use as a medicament, or for use in a diagnostic method, are also provided.
The present invention relates to a method for radioactive labeling of a precursor with 225Ac comprising freeze-drying the precursor before labeling. The present invention further relates to the 225Ac-labeled precursor obtained in said method for use in the treatment of cancer. The present invention also relates to a kit for radioactive labeling of a precursor with 225Ac.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
The present invention relates to compounds that bind to prostate-specific membrane antigen (PSMA) comprising a PSMA binding moiety, a linker group comprising a silicon-fluoride acceptor (SIFA) moiety and a chelator moiety, optionally containing a chelated nonradioactive or radioactive cation, wherein the SIFA moiety comprises a covalent bond between a silicon and a fluorine atom which can be 18F. The disclosure includes compounds of Formula (1) or a pharmaceutically acceptable salt or any individual isomer thereof, wherein CM is defined herein, and their use as cancer diagnostic or imaging agents.
The present invention relates to compounds that bind to prostate-specific membrane antigen (PSMA) comprising a PSMA binding moiety, a linker group comprising a silicon-fluoride acceptor (SIFA) moiety and a chelator moiety, optionally containing a chelated nonradioactive or radioactive cation, wherein the SIFA moiety comprises a covalent bond between a silicon and a fluorine atom which can be 18F. The disclosure includes compounds of Formula (1) or a pharmaceutically acceptable salt or any individual isomer thereof, wherein CM is defined herein, and their use as cancer diagnostic or imaging agents.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
62.
DNA ORIGAMI ENCODING FOR GENE EXPRESSION AND COTRANSFECTION
The present invention relates to a nucleic acid nanostructure comprising at least one scaffold strand and a plurality of staple strands, wherein said nanostructure, preferably said at least one scaffold strand, comprises at least one nucleic acid sequence encoding a gene. The present invention further relates to a composition comprising a nucleic acid nanostructure, and to a collection of nucleic acid sequences or collection of plasmids encoding a nucleic acid nanostructure. Furthermore, the present invention relates to a nucleic acid nanostructure or composition comprising a nucleic acid nanostructure for use in medicine; preferably for use in a method of preventing, treating and/or diagnosing a disease or disorder. The present invention also relates to a method of expressing a gene from a nucleic acid nanostructure, and to a use of a nanostructure or of a composition for gene expression.
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (Allemagne)
Technische Universität München (Allemagne)
Inventeur(s)
Heikenwaelder, Mathias
Knolle, Percy
Pfister, Dominik
Dudek, Michael
Abrégé
The present invention concerns the field of diagnostics and patient stratification for cancer therapy. In particular, it relates to a method for assessing a treatment response associated with immunotherapy in a subject in need thereof comprising the steps of determining hepatic auto-aggressive CD8 positive (+) PD-1 positive (+) T cells exhibiting traits of activation and exhaustion or CD8+ T cell precursors thereof in a sample of a subject in need of immunotherapy or in a data set comprising imaging data of a subject in need of immunotherapy, and assessing the treatment response associated with immunotherapy based on the presence, absence or abundance of said hepatic auto-aggressive CD8+ PD-1+ T-cells exhibiting traits of activation or exhaustion or CD8+ T cell precursors thereof. Further contemplated is a method for recommending immunotherapy for a subject or a method for treating a subject by immunotherapy. The present invention also provides a diagnostic device for carrying out the method of the present invention.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention relates to a three-dimensional polynucleotide-based open shells for encapsulating a virus or viral particle, to a composition comprising a mixture of such three-dimensional polynucleotide-based open shells, to a composition comprising a virus or viral particle encapsulated by such three-dimensional polynucleotide-based open shells, and to a method for encapsulating a virus, a viral particle or a subviral particle by using such a three-dimensional polynucleotide-based open shells.
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
65.
OLEIC ACID SUNFLOWER MUTANTS AND METHODS FOR DETECTION
Helianthus annuusHelianthus annuusHelianthus annuusHelianthus annuusHelianthus annuus, or the cell, tissue, organ, seed, or part of the plant for producing an oil product having an optimized oil fatty acid profile.
The invention relates to a method for the synthesis of ammonia (18), in which a gas mixture (make-up gas) (1) comprising hydrogen and nitrogen is provided in a first operating mode with a flow rate that is above a threshold value and in a second operating mode with a flow rate that is below this threshold value in order to form an ammonia synthesis gas (5), which is reacted in an ammonia reactor (R) in at least one first catalyst bed (K1) and in a second catalyst bed (K2), connected to the first catalyst bed, to form a synthesis product (16) containing ammonia, wherein in a cooling device (E3) arranged between the first (K1) and the second catalyst bed (K2), non-reacted ammonia synthesis gas (8) is used as a cooling agent in order to reduce the temperature of an ammonia synthesis gas (12) partially reacted in the first catalyst bed (K1) before it is forwarded to the second catalyst bed (K2), wherein in the second operating mode, the higher the flow rate of the provided make-up gas (1), the greater the reduction in temperature of the partially reacted ammonia synthesis gas (12). What is characteristic is that the ammonia synthesis gas (12) partially reacted in the first catalyst bed (K1) is cooled by indirectly exchanging heat with provided ammonia synthesis gas (8).
B01J 8/04 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solidesAppareillage pour de tels procédés avec des particules immobiles, p. ex. dans des lits fixes le fluide passant successivement à travers plusieurs lits
C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
F25J 3/04 - Procédés ou appareils pour séparer les constituants des mélanges gazeux impliquant l'emploi d'une liquéfaction ou d'une solidification par rectification, c.-à-d. par échange continuel de chaleur et de matière entre un courant de vapeur et un courant de liquide pour l'air
67.
BIONIC JOINT AND A PROSTHESIS FOR REPLACING AN ELBOW JOINT
An artificial joint for a prosthesis or robot arm, the artificial joint comprising a first rigid link, a second rigid link, a compliant joint rotatably connecting the first rigid link and the second rigid link with respect to a principal plane of rotation, and comprising an elastic link extending between the first rigid link and the second rigid link, and a first string section and a second string section both extending between the first rigid link and the second rigid link, being arranged on opposite sides with respect to the compliant joint, such that shortening one of the first string section and of the second string section and lengthening the other one of the first string section and of the second string section drives a rotation of the first rigid link and the second rigid link with respect to each other in the principal plane of rotation.
A computer-implemented method for determining the refractive power of an intraocular lens includes providing a physical model for determining refractive power and training a machine learning system with clinical ophthalmological training data and associated desired results to form a learning model for determining the refractive power. A loss function for training includes: a first component taking into account clinical ophthalmological training data and associated and desired results and a second component taking into account limitations of the physical model wherein a loss function component value is greater the further a predicted value of the refractive power during the training is from results of the physical model with the same clinical ophthalmological training data as input values. Moreover, the method includes providing ophthalmological data of a patient and predicting the refractive power of the intraocular lens to be used by means of the trained machine learning system.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
The invention proposes a process (100, 200) for producing a hydrogen product (320) essentially containing hydrogen, the process comprising using a reforming (31) and a water-gas shift (35) to provide a first component mixture (312) that contains carbon dioxide and components with a lower boiling point than carbon dioxide, including hydrogen and carbon monoxide, using a first adsorptive separation (36) to provide the hydrogen product and a second component mixture (305, 608) that contains a respective proportion of each of the components with a lower boiling point than carbon dioxide, using a carbon dioxide removal (50, 60) that comprises a cryogenic separation (54) and a second adsorptive separation (55, 65) to provide a carbon dioxide product (504), which essentially contains carbon dioxide, and a third component mixture (507, 607) which is essentially free from carbon dioxide and contains a respective proportion of each of the components with a lower boiling point than carbon dioxide, and the process (100) is conducted in a first alternative in which the first component mixture (312) or a portion thereof is supplied to the first adsorptive separation (36) without prior separation in the carbon dioxide removal (50), the second component mixture (305) containing carbon dioxide, wherein the second component mixture (305) or a portion thereof is supplied to the carbon dioxide removal (50), and wherein the third component mixture (507) or a portion thereof is supplied to a solid oxide fuel cell unit (10), or the process (200) is conducted in a second alternative in which the first component mixture (312) or a portion thereof is supplied to the carbon dioxide removal (60) without prior separation in the first adsorptive separation (36), the second component mixture (608) essentially being free from carbon dioxide, wherein the third component mixture (607) or a portion thereof is supplied to the first adsorptive separation (36), and wherein the second component mixture (608) or a portion thereof is supplied to the solid oxide fuel cell unit (10). The present invention also provides a corresponding system.
C01B 3/38 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants avec des catalyseurs
C01B 3/48 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants suivie par une réaction de la vapeur d'eau avec l'oxyde de carbone
C01B 3/50 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification
H01M 8/10 - Éléments à combustible avec électrolytes solides
F25J 3/02 - Procédés ou appareils pour séparer les constituants des mélanges gazeux impliquant l'emploi d'une liquéfaction ou d'une solidification par rectification, c.-à-d. par échange continuel de chaleur et de matière entre un courant de vapeur et un courant de liquide
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
Provided is a chelate complex comprising (a) a rare earth metal cation M; (b) a chelate ligand of formula (CL1 A) or (CL1 B) c) at least one anionic nucleophilic ligand LN which is coordinated as a further ligand to the rare earth metal cation; and d) optionally one or more neutral donor ligands LD coordinated as ligands to the rare earth metal cation. Moreover, provided are a process for the preparation of a chelate complex, a process for the preparation of a polymer comprising a polymerization reaction of chiral cyclic ester monomers, and a poly(3-hydroxy butyrate) polymer which can be provided by the process.
The invention relates to a method for producing a hydrogen-containing product (111) using electrolysis (10), wherein the electrolysis (10) is carried out using one or more electrolysis stacks having a plurality of electrolysis cells, wherein during a continuous or discontinuous production period between a first time (BoL) and a second time (EoL) an electrolysis voltage present on the electrolysis stack is applied to the electrolysis cells, and wherein during the production period the electrolysis cells are operated with an operating temperature set to a default value. According to the invention, the default value for the operating temperature is increased during a continuous or discontinuous partial period, which is after a predefined time during the operating period. The present invention also relates to a corresponding system (100).
The invention relates to a process (1000, 2000) for preparing methanol, in which a methanol synthesis feedstock (101) containing hydrogen and a carbon dioxide undergoes a methanol synthesis (100) with the formation of a raw product mixture (103) containing methanol, components that boil lower than methanol and components that boil higher than methanol, wherein at least some of the raw product mixture (103) undergoes a methanol purification (400) with the formation of a methanol product (405) and one or several light gas fractions (401, 403) that are depleted of methanol with respect to the raw product mixture (103) and are enriched with at least one of the components that boil lower than methanol, wherein at least some of the hydrogen in the methanol synthesis feedstock (101) is provided using electrolysis (200, 500), and wherein at least some of the light gas fraction (401, 403) or some of at least one of the several light gas fractions (401, 403) is returned to the electrolysis (200, 500) or to a further process step (310) used to provide the methanol synthesis feedstock (101). The present invention also relates to a corresponding system.
C07C 29/151 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par réduction exclusivement des oxydes de carbone avec de l'hydrogène ou des gaz contenant de l'hydrogène
A system for electro-writing of a polymer melt comprises a print-head and a feed mechanism configured to controllably feed solid polymer base material towards the print-head, wherein the print-head comprises a nozzle, a heater and an insulating spacer, wherein the print-head is configured to eject the polymer melt via the nozzle, wherein the nozzle is configured to be held at a selectable electric potential, wherein the heater is arranged in the print-head and proximate the nozzle, wherein the heater is configured to heat the solid polymer base material beyond its melting point to create the polymer melt in the print-head, wherein insulating spacer is arranged between the heater and the nozzle, wherein the insulating spacer electrically insulates the heater and the nozzle, and wherein the insulating spacer is at least partially surrounded by the heater.
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
H133 alkyl, -OH, -SH, -F, and -Cl, Phe, 1-Nal, 2-Nal, Tyr or p-Amino-Phe, Xaa2 is an N-methyl amino acid, wherein the N-methyl group is at the alpha carbon, and preferably an N-methyl amino acid containing an aliphatic side chain, wherein the N-methyl group is at the alpha carbon, Xaa3 is an amino acid with an acidic side chain at neutral pH, and Xaa4 is an amino acid with an aromatic side chain or an amide thereof.
The present invention relates to multi-peptide structures comprising at least one heterogenous functional site wherein the at least one heterogenous functional site is composed of at least two homologous peptides, which differ by at least one amino acid, a method for providing such multi-peptide structures, compositions comprising such multi-peptide structures as well as the use of such multi-peptide structures and compositions as an universal anti-microbial agent, in particular in medicine, chemistry, biotechnology, agriculture and/or food industry.
A computer-implemented method for range query processing of complex geometric data in a database with respect to a query distance to a query object, said method comprising the steps of determining a buffered query object with respect to the query object, wherein a geometric footprint of the buffered query object is increased with respect to the query object based on the query distance; determining a buffered query filter for the buffered query object using a filter function, wherein the filter function comprises determining a mapping of an overlapped cell of a grid to a corresponding element of the buffered query filter, the overlapped cell being overlapped by the buffered query object on the grid; and filtering out complex geometric data objects in the database for which the filter function generates corresponding filter objects, which are not a subset of the buffered query filter and/or which have an empty intersection with the buffered query filter.
The invention refers to an inhibitor of at least one S-adenosylmethionine (SAM) cycle enzyme for use in preventing or treating coronavirus disease 2019 (COVID-19) in a subject, or for use in preventing or treating of infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a subject, wherein the at least one SAM cycle enzyme is selected from the group consisting of methionine adenosyltransferase, betaine-homocysteine methyltransferase, methionine synthase, methionine synthase reductase and S-adenosylhomocys.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61P 31/14 - Antiviraux pour le traitement des virus ARN
TECHNISCHE UNIVERSITÄT MÜNCHEN - KLINIKUM RECHTS DER ISAR (Allemagne)
Inventeur(s)
Wester, Hans-Jürgen
Wurzer, Alexander Josef
Eiber, Matthias Johannes
Abrégé
The present invention relates to compounds of the Formula (1) and pharmaceutically acceptable salts thereof, wherein M3+ is as defined herein, and their use as cancer diagnostic or imaging agents.
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
The present invention relates to variants of TEV protease that have - compared to the wildtype enzyme - increased stability and catalytic activity as well as altered substrate specificity. The invention further relates to compositions comprising these variants as well as uses thereof and methods in which these variants are employed.
The present invention relates to a coated membrane containing:
a membrane with a front and a rear face,
a catalyst-containing coating which is provided on the front face of the membrane,
the catalyst containing
a support material which has a BET surface area of maximally 80 m2/g,
an iridium-containing coating which is provided on the support material and contains an iridium oxide, an iridium hydroxide or an iridium hydroxide oxide or a mixture of at least two of these iridium compounds,
wherein the catalyst contains iridium in a quantity of maximally 60 wt. %, and
the coating provided on the membrane front face has an iridium content of maximally 0.4 mg iridium/cm2.
C25B 9/23 - Cellules comprenant des électrodes fixes de dimensions stablesAssemblages de leurs éléments de structure avec des diaphragmes comprenant des membranes échangeuses d'ions dans ou sur lesquelles est incrusté du matériau pour électrode
C25B 11/075 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’un seul élément catalytique ou composé catalytique
C25B 11/054 - Électrodes comportant des électro-catalyseurs sur un support
C25B 13/08 - DiaphragmesÉléments d'espacement caractérisés par le matériau à base de matériaux organiques
C25B 11/067 - Composé inorganique, p. ex. oxyde d'indium-étain, silice ou oxydes de titane
82.
SYSTEMS, METHODS, AND COMPUTER-ACESSIBLE MEDIUM FOR PROVIDING PREDICTORS OF LOW RISK FOR DELIRIUM DURING ANESTHESIA EMERGENCE
THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (USA)
TECHNISCHE UNIVERSITÄT MÜNCHEN (Allemagne)
Inventeur(s)
Lutz, Rieke
Müller, Claudia
Dragovic, Srdjan
Garcia, Paul, S.
Schneider, Gerhard
Kreuzer, Matthias
Kratzer, Stephan
Schneider, Frederick
Ribbe, Katharina
Anders, Malte
Schmid, Sebastian
Abrégé
Exemplary system, method and computer-accessible medium can be provided to monitor electroencephalography (EEG) data from the patient during an emergence from a general anesthesia previously provided to the patient, and predicting neurocognitive impairment based on a slope of EEG power. The neurocognitive impairment predicted can be delirium or it may be a predictor of long-term impairment such as Alzheimers. Further, the system and method can be used to direct a medical intervention based on the preditcted neurocognitive impairment.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/291 - Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
A computer-implemented method is provided for generating, based on a first digital image associated with a first viewpoint, a virtual mirror image according to a perspective view associated with a second viewpoint. The method comprises determining a bisector plane of the first viewpoint and the second viewpoint. The method further comprises computing the virtual mirror image based on a projection of the first digital image onto the bisector plane.
The present invention relates to a method for producing at least one target compound selected from a terpenoid, a phenolic compound, a vitamin, and a combination thereof in a yeast cell from the family Trichosporonaceae. The present invention further relates to a composition comprising at least one target compound selected from a terpenoid, a phenolic compound, a vitamin, and a combination thereof.
C12P 17/06 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'oxygène comme unique hétéro-atome du cycle contenant un hétérocycle à six chaînons, p. ex. fluorescéine
C12P 7/22 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle aromatiques
85.
SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS
The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae (Ia, Ib, Ic) as well as to compounds suitable for use in radiopharmacy comprising such groups, wherein R1and R2are each a linear or branched C3 to C10 alkyl group and R3is selected from (i) -OH or -O-, (ii) a sugar moiety or an amino sugar moiety, (iii) an amino acid moiety or an oligopeptide moiety, (iv) a PEG moiety; and from combinations of two or more of (ii), (iii) and (iv).
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07D 259/00 - Composés hétérocycliques contenant des cycles comportant plus de quatre atomes d'azote comme uniques hétéro-atomes du cycle
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07K 5/062 - Dipeptides la chaîne latérale du premier amino-acide étant acyclique, p. ex. Gly, Ala
C07K 5/068 - Dipeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
86.
A MICROELECTRODE FOR ENCAPSULATING A SINGLE CELL AND/OR FOR BEING IMPLANTED INTO A BIOLOGICAL TISSUE, A SYSTEM COMPRISING THE MICROELECTRODE, AND ITS MANUFACTURING METHOD
A microelectrode for encapsulating a single cell and/or for being implanted into a biological tissue, wherein the microelectrode comprises a multilayer sheet comprising a polymer compound layer (1, 1A, 1B), and a first compound layer (2, 2A, 2B) being a crystalline monolayer of a first compound or a stack of multiple crystalline monolayers of a first compound, the first compound being semiconductive or electrically insulative, the first compound layer (2, 2A, 2B) being deposited on the polymer compound layer (1, 1A, 1B), wherein the multilayer sheet is structured such that when no external force is applied to the multilayer sheet, the multilayer sheet forms a cylindrical form having an internal hollow space and a longitudinal axis, such that one of said layers forms an outer layer of the cylindrical form and another of said layers forms an inner layer of the cylindrical form.
A61B 5/293 - Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG] invasives
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
B82Y 40/00 - Fabrication ou traitement des nanostructures
87.
Apparatus and method for determining a response of a device under test to an electrical pulse generated by a pulse generator
An apparatus for determining a response of a device under test to an electrical pulse generated by a pulse generator. The apparatus can include a conductor for coupling the electrical pulse generator to the device under test and at least two sensing probes connected to the conductor. Each of the at least two sensing probes can be positioned at one of at least two measurement points and can be configured to generate a signal in direct proportion to a current flowing in or a voltage applied to the conductor at the corresponding measurement point. A determination device can be configured to determine the response of the device under test to the electrical pulse based on the signals generated by the at least two sensing probes nd the transit times of the electrical pulse between these different measurement points.
G01R 31/00 - Dispositions pour tester les propriétés électriquesDispositions pour la localisation des pannes électriquesDispositions pour tests électriques caractérisées par ce qui est testé, non prévues ailleurs
88.
ANALYSIS OF TISSUE SAMPLES USING QUANTITATIVE PHASE-CONTRAST MICROSCOPY
Disclosed herein is a method of analyzing a tissue sample using a quantitative phase-contrast microscope as well as a corresponding microfluidic system and a corresponding device. The method comprises providing the tissue sample in a sample volume of a microfluidic system, wherein the tissue sample comprises a plurality of biological cells forming a continuous tissue material. At least a part of the tissue sample is dissolved into single cells and/or cell aggregates in a carrier fluid in the sample volume. A flow of the carrier fluid is generated from the sample volume to a measurement volume of the microfluidic system and a first phase shift image of the single cells and/or cell aggregates in the measurement volume is taken with the quantitative phase-contrast microscope.
Provided is a photon detector and method of manufacturing a photon detector. The method comprises forming (44) an oxide layer (14), forming (46) a superconducting material layer (24), and forming (48) an oxidation barrier layer (16) between, and abutting, the oxide layer (14) and the superconducting material layer (24).
G01J 5/20 - Pyrométrie des radiations, p. ex. thermométrie infrarouge ou optique en utilisant des détecteurs électriques de radiations en utilisant des éléments résistants, thermorésistants ou semi-conducteurs sensibles aux radiations, p. ex. des dispositifs photoconducteurs
90.
OXYGEN EVOLUTION CATALYST, PRODUCTION AND USE THEREOF, MEMBRANE ELECTRODE ASSEMBLY, AND FUEL CELL OR ELECTROLYSIS CELL
An oxygen evolution reaction catalyst includes a solid solution of at least one valve metal oxide and at least one noble metal oxide, wherein the valve metal oxide is selected from oxides of titanium, oxides of niobium, oxides of tungsten and oxides of tantalum, the noble metal oxide is selected from oxides of iridium, oxides of ruthenium and/or mixtures and/or alloys thereof, the BET specific surface area of the solid solution is greater than 10 m2/g, and the oxygen evolution reaction catalyst exhibits a weight loss of less than 2% by weight upon exposure of the oxygen evolution reaction catalyst to a 3.3 vol % hydrogen stream in argon at a temperature of 80° C. for 12 hours.
Encoding device for encoding vibrotactile multichannel signals, includes an encoder input module configured to receive a multichannel signal; a transform module adapted to execute a discrete wavelet transform of each channel of the multichannel signal and to generate a respective frequency range representation of each channel; a psychohaptic model unit designed to allocate to each channel, based on the respective frequency range representation, a mathematical representation of human perception of the channel; a clustering module configured to group, based on the allocated mathematical representation and a similarity measure of the channels, the wavelet-transformed channels of each multichannel signal into clusters, wherein each cluster is allocated a reference channel; a reference encoding module designed to quantize and compress wavelet coefficients of the reference channels which result from the performed discrete wavelet transform of the reference channels; a differential encoding module configured to encode the channels within a cluster, which are not a reference channel, in relation to the reference channel or at least one other channel of the cluster; and an encoder output module which outputs the clustered, compressed channels of each multichannel signal as a bit stream.
A system for electro-spinning/writing of a polymer material, the system comprising a print-head configured to eject the polymer material via a nozzle, a collector configured to receive the polymer material ejected from the nozzle, a displacement assembly configured to adjust a distance between the print-head and the collector, and a vat containing or configured to contain a liquid, wherein the vat is further configured to receive the collector, wherein the displacement assembly is configured to retract the collector and at least a part of the polymer material received by the collector into the liquid in the vat in accordance with a height of the received polymer material.
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
B29C 64/232 - Moyens d’entraînement pour un mouvement le long de l'axe orthogonal au plan d’une couche
n11010 hydrocarbon group; wherein X is a hydrosilylable functionality, selected from a vinyl-, allyl-, alkinyl-, carbonyl-, imine-, nitrile-, isonitrile- and azo group; wherein R112012020 hydrocarbonoxy group, (iii) a silyl group -SiR4R5R6, wherein R4, R5, R6166 hydrocarbon group, (iv) an amino group -NRY22, wherein Ry12020 hydrocarbon group and (iv.iii) a silyl group -SiR4R5R6, and (v) an imino group -N=CR7R8, wherein R7, R812020 hydrocarbon group and a silyl group -SiR4R5R6; wherein R2, R312020 hydrocarbon group, a silyl group -SiR4R5R62yy-[SiR9R10χχ-[SiR11R12R13], wherein R9to R13independently of each other are selected from the group including methyl, ethyl, phenyl, hydrogen, ethinyl and vinyl, and wherein index x is zero or an integer from 1 to 200 and index y is zero or an integer from 1 to 10, and wherein R2and R3 can be part of a cyclic group.
The present invention relates to a method for preparing oligosaccharides which can be used among others as food additives to reduce calorie content, to sweeten food products, to increase the fiber content of food products, to improve the texture of food products and to stimulate the gut microbiome bacteria. Furthermore they can be applied in the fields of animal feed, or other applications. More particularly, this invention is directed to a high temperature hydrolysis of xyloglucan polysaccharide to defined xyloglucan oligosaccharides. The invention further relates to oligosaccharide hydrolysates produced with the method of the invention and to the use of said oligosaccharide hydrolysates in human and/or animal nutrition, as prebiotic or other uses. Further provided are novel endoglucanases for use in the method of the invention as well as in other applications.
The present invention relates the use of an anti-inflammatory agent for inhibiting and/or preventing damage of a peripheral ganglion in a subject, particularly in a subject suffering from a cardiac disease. The present invention also relates to the use of an anti-inflammatory agent for preserving cardiac innervation in a subject suffering from cardiac disease. Further, the present invention relates to method for identifying a subject being at risk of damage of a peripheral ganglion, comprising determining in said subject at least one parameter associated with a risk of damage ganglion damage, wherein the parameter may be a ganglion-specific biomarker. Furthermore, the invention relates to the use of a modulator of at least one of said ganglion-specific biomarkers for preventing damage of a peripheral ganglion in a subject.
A61K 31/663 - Composés ayant plusieurs groupes acide du phosphore ou leurs esters, p. ex. acide clodronique, acide pamidronique
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present invention relates to an improved methanation process, wherein energy released during the methanation process is used to drive a turbocharger to drive and/or maintain the process. The present invention is further concerned with a system for the production of methane-enriched gas and power from hydrogen and carbon-containing starting materials comprising at least one methanation reactor and at least one turbocharger.
C10K 3/00 - Modification de la composition chimique des gaz combustibles contenant l'oxyde de carbone en vue de produire un carburant amélioré, p. ex. un carburant de pouvoir calorifique différent qui peut ne pas contenir d'oxyde de carbone
97.
SUBSTRATE FOR IMPLANTABLE MICROELECTRODES, ELECTRODE ELEMENT AND ELECTRODE SYSTEM, AND METHOD OF MANUFACTURING THEREOF
A substrate (A) for implantable microelectrodes comprising a substrate base layer (1) being a polymer compound layer, wherein the substrate base layer (1) has a thickness (d1) in the z- direction and comprises a first surface (1-1) and a second surface (1-2), each of the first surface (1- 1) and the second surface (1-2) extending in the x-direction and the y-direction, the second surface (1-2) being opposite to the first surface (1-1) in the z-direction, wherein the substrate base layer (1) consists of a hybrid material of a hydrophobic part and a hydrophilic part, wherein the hybrid material is based on a mixture, the mixture comprising (a) a photoinitiator being able to be activated by exposure to light, (b) a first component comprising a first hydrophobic monomer, a first hydrophobic oligomer, a first hydrophobic polymer or a first hydrophobic copolymer, wherein the first hydrophobic monomer or oligomer or polymer or copolymer of the first component comprises a first functional group, wherein the first functional group is able to be activated by the activated photoinitiator, so that the first component is able to be polymerized through the first functional groups, (c) a second component comprising a hydrophilic monomer or a hydrophilic oligomer or a hydrophilic polymer or a hydrophilic copolymer, wherein the hydrophilic monomer or oligomer or polymer or copolymer comprises a second functional group, wherein the second functional group is able to be activated by the activated photoinitiator, so that the second component is able to be polymerized through the second functional groups, and so that the first component and the second component are able to be co-polymerized through the first functional groups and the second functional groups, and wherein the molecular weight (Mwa) of the first component is larger than the molecular weight (Mwb) of the second component, wherein the first surface (1-1) is more hydrophilic than the second surface (1-2).
Proposed is a process (100, 200, 300) for catalytic preparation of methanol, wherein a reactor system (10) having a first reaction zone (11) and a second reaction zone (12) is used, wherein the first reaction zone (11) and the second reaction zone (12) are operated adiabatically and each have a catalytic reaction zone (11), wherein at least a portion of a gas mixture flowing from the first reaction zone (11) is transferred into the second reaction zone (12), wherein a first feed stream is introduced at a first temperature level into the reactor system (10) upstream of the first reaction zone (11), wherein a second feed stream is introduced at a second temperature level into the reactor system (10) between the first reaction zone (11) and the second reaction zone (12), and wherein the first temperature range is above the second temperature range. The present invention also relates to a corresponding system.
C07C 29/152 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par réduction exclusivement des oxydes de carbone avec de l'hydrogène ou des gaz contenant de l'hydrogène caractérisée par le réacteur utilisé
FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Allemagne)
TECHNISCHE UNIVERSITÄT MÜNCHEN (Allemagne)
Inventeur(s)
Volk, Wolfram
Günther, Daniel
Klan, Steffen
Erhard, Patricia
Hartmann, Christoph
Lechner, Philipp
Steinlehner, Florian
Abrégé
The invention relates to a device (10) and a method for moulding a curable moulding compound (202), comprising the steps of: - receiving a curable moulding compound (202), which is in a liquid state, in a cavity (14) that is delimited by a first mould part (100) and at least a second mould part (101) of a moulding tool (12); - generating at least one first relative movement between the first and the second mould part (100, 101) such that the cavity (14) becomes smaller; - curing the moulding compound (202).
B22D 17/20 - AccessoiresCoulée sous pression ou moulage par injection, c.-à-d. moulage en introduisant le métal dans le moule sous haute pression Parties constitutives
B22D 18/02 - Coulée avec pression, utilisant des dispositifs presseurs mécaniques, p. ex. matriçage semi-liquide
B22D 17/22 - Moules métalliquesPlaques de moulesSupports de moulesÉquipement de refroidissement des moulesAccessoires pour l'extraction et l'éjection des pièces hors du moule
B22D 27/11 - Traitement du métal dans le moule pendant qu'il est liquide ou plastique en appliquant une pression en utilisant un dispositif presseur mécanique
B29C 33/34 - Moules ou noyauxLeurs détails ou accessoires mobiles, p. ex. vers le, ou à partir du poste de moulage
B29C 39/40 - Dispositions pour compenser des changements de volume, p. ex. le retrait
B29C 43/04 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés en utilisant des moules mobiles
B29C 43/10 - Pressage isostatique, c.-à-d. en utilisant des organes presseurs non rigides coopérant avec des organes rigides ou des matrices
B29C 43/36 - Moules pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés
B29C 45/04 - Appareils de moulage par injection avec moules mobiles
B29C 45/56 - Moyens pour plastifier ou homogénéiser la matière à mouler ou pour la forcer dans le moule utilisant des éléments de moules mobiles pendant ou après l'injection, p. ex. pour le moulage par injection-pressage
The present invention relates to a nucleic acid molecule encoding a fusion protein comprising (i) a secretory signal peptide; (ii) a lipocalin-derived binding protein specifically binding to an exogenous ligand; and (iii) a glycosylphosphatidylinositol (GPI) anchored and/or transmembrane domain.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
